Reference health
Cancer epigenetics: Moving forward
146/146 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 146 checked references that resolve
resolves10.1038/1831654a0
Canalization of Development and Genetic Assimilation of Acquired Characters
resolves10.1016/j.cell.2016.12.002
The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery
resolves10.1126/science.aad9780
Epigenetic balance of gene expression by Polycomb and COMPASS families
resolves10.3389/fped.2017.00004
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
resolves10.1038/nature11606
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
resolves10.1038/nrc.2016.83
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
resolves10.1016/j.molcel.2013.02.013
Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put
resolves10.1038/nrc3130
A decade of exploring the cancer epigenome — biological and translational implications
resolves10.1016/j.ccr.2010.12.014
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
resolves10.18632/oncotarget.14150
AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis
resolves10.1038/ng.2928
Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
resolves10.1182/blood-2013-04-427724
Perspectives and future directions for epigenetics in hematology
resolves10.1038/s41598-017-12010-5
Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses
resolves10.1038/s41467-017-01251-7
High-intensity UV laser ChIP-seq for the study of protein-DNA interactions in living cells
resolves10.1038/nature13981
Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells
resolves10.1016/j.stem.2016.10.019
DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation
resolves10.1016/j.celrep.2016.10.054
Distinct Trends of DNA Methylation Patterning in the Innate and Adaptive Immune Systems
resolves10.1056/NEJMoa1301689
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
resolves10.1016/j.cell.2017.01.021
CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression
resolves10.1016/j.ccell.2016.09.014
Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage
resolves10.1038/ng.2443
Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia
resolves10.1038/ng.3291
Whole-genome fingerprint of the DNA methylome during human B cell differentiation
resolves10.1038/leu.2014.252
A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact
resolves10.1038/ncomms11938
Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks
resolves10.1016/j.ccr.2009.12.042
PML-RARα/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia
resolves10.1016/j.ccr.2009.12.045
PML/RARα Targets Promoter Regions Containing PU.1 Consensus and RARE Half Sites in Acute Promyelocytic Leukemia
resolves10.1002/pbc.26251
DNA methylation profiling of pediatric B‐cell lymphoblastic leukemia with <i>KMT2A</i> rearrangement identifies hypomethylation at enhancer sites
resolves10.1038/nm.3832
DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia
resolves10.1016/j.leukres.2013.07.016
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia
resolves10.1016/j.leukres.2013.05.012
High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia
resolves10.1172/JCI78440
Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
resolves10.4161/epi.27322
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene
<i>IL3</i>
resolves10.1182/blood-2012-05-429050
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia
resolves10.1182/blood.V91.9.3134
Expression of a Knocked-In AML1-ETO Leukemia Gene Inhibits the Establishment of Normal Definitive Hematopoiesis and Directly Generates Dysplastic Hematopoietic Progenitors
resolves10.1128/MCB.15.4.1974
The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation
resolves10.1016/j.celrep.2016.08.082
The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs
resolves10.1016/j.celrep.2014.08.024
Identification of a Dynamic Core Transcriptional Network in t(8;21) AML that Regulates Differentiation Block and Self-Renewal
resolves10.1038/sj.leu.2403396
Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal
resolves10.1038/86515
AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
resolves10.1182/blood-2013-03-487884
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
resolves10.1101/gr.180240.114
Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers
resolves10.1182/blood-2010-04-279539
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
resolves10.1182/blood-2010-07-298349
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
resolves10.1158/1535-7163.MCT-12-0721
Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
resolves10.1182/blood-2015-09-665018
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
resolves10.18632/oncotarget.10033
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
resolves10.1016/j.ccr.2007.04.009
Role of the Polycomb Repressive Complex 2 in Acute Promyelocytic Leukemia
resolves10.1371/journal.pone.0111840
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
resolves10.5306/wjco.v5.i3.509
Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal
resolves10.1038/ncomms6899
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value
resolves10.4161/epi.22561
<i>BRCA1</i>epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
resolves10.1200/JCO.2010.30.1010
<i>BRCA1</i> CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors
resolves10.1186/1471-2407-9-217
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer
resolves10.1158/1078-0432.CCR-08-1981
Hypermethylated Genes as Biomarkers of Cancer in Women with Pathologic Nipple Discharge
resolves10.1007/s10549-007-9620-x
Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions
resolves10.1038/srep33435
DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients
resolves10.1038/s41598-017-06790-z
The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer
resolves10.1158/0008-5472.CAN-08-3907
Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome
resolves10.1007/s10549-014-3089-1
Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses’ Health Study
resolves10.2217/epi-2016-0015
H3K4 Acetylation, H3K9 Acetylation and H3K27 Methylation in Breast Tumor Molecular Subtypes
resolves10.1186/s13148-016-0201-x
Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model
resolves10.1038/ncomms10751
RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer
resolves10.1186/gb-2007-8-10-r214
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
resolves10.1186/1471-2164-14-643
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
resolves10.1038/nature12108
The shaping and functional consequences of the microRNA landscape in breast cancer
resolves10.1186/bcr3127
Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers
resolves10.1007/s13402-015-0239-3
Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers
resolves10.1186/bcr2257
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neureceptor status in breast cancer
resolves10.1016/j.mce.2011.12.020
Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer
resolves10.1038/onc.2014.298
Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a
resolves10.3892/etm.2013.915
miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer
resolves10.1007/s10549-014-3037-0
Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
resolves10.2144/000113837
Quantitative Analysis of Micrornas in Tissue Microarrays by in Situ Hybridization
resolves10.1038/jhg.2016.89
Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes
resolves10.1200/JCO.2008.18.1370
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
resolves10.1016/j.celrep.2016.10.057
Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types
resolves10.1200/JCO.2013.55.0491
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
resolves10.1258/ebm.2011.011007
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity
resolves10.1016/j.molonc.2015.10.008
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
resolves10.1016/j.ccell.2015.03.001
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
resolves10.1016/j.immuni.2016.10.032
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
resolves10.1016/j.immuni.2016.10.021
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
resolves10.1126/science.aah6893
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
resolves10.1038/bjc.2011.156
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
resolves10.1080/2162402X.2016.1219008
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
resolves10.1016/j.anndiagpath.2011.04.008
Molecularly confirmed primary malignant rhabdoid tumor of the urinary bladder: implications of accurate diagnosis
resolves10.1016/j.ajhg.2010.01.013
Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition Syndrome
resolves10.1097/PAS.0b013e3182196a39
Nonsense Mutation and Inactivation of SMARCA4 (BRG1) in an Atypical Teratoid/Rhabdoid Tumor Showing Retained SMARCB1 (INI1) Expression
resolves10.1002/gcc.2870020308
Malignant rhabdoid tumor: A highly malignant childhood tumor with minimal karyotypic changes
resolves10.1128/MCB.21.10.3598-3603.2001
Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in Mice
resolves10.1073/pnas.250492697
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice
resolves10.1038/sj.onc.1205706
Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1arrest associated with induction of p16ink4a and activation of RB
resolves10.1128/MCB.22.16.5975-5988.2002
Cell Cycle Arrest and Repression of Cyclin D1 Transcription by INI1/hSNF5
resolves10.1158/0008-5472.CAN-05-1896
Loss of the
<i>hSNF5</i>
Gene Concomitantly Inactivates p21CIP/WAF1 and p16INK4a Activity Associated with Replicative Senescence in A204 Rhabdoid Tumor Cells
resolves10.1073/pnas.0509014102
Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation
resolves10.1097/NEN.0b013e31822146ca
p16<sup>INK4A</sup>and p14<sup>ARF</sup>Tumor Suppressor Pathways Are Deregulated in Malignant Rhabdoid Tumors
resolves10.1038/nm.2251
Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway
resolves10.1038/onc.2013.37
Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5
resolves10.1038/labinvest.2010.66
Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets
resolves10.1073/pnas.1303800110
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
resolves10.1002/pbc.26218
Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program
resolves10.1172/JCI64400
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers
resolves10.1002/pbc.24315
Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
resolves10.1016/S1470-2045(15)70114-2
Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis
resolves10.1016/j.ccell.2016.02.001
Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes
resolves10.1016/j.molcel.2015.02.014
Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
resolves10.1038/nbt.2282
Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells
resolves10.1038/nrg3542
Single-cell sequencing-based technologies will revolutionize whole-organism science
resolves10.1186/s13059-016-0944-x
Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity
resolves10.1126/science.1169786
The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain
resolves10.1158/1078-0432.CCR-12-2037
Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances
resolves10.1186/s13059-017-1177-3
cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes
resolves10.1186/s13072-015-0050-4
Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome
resolves10.1186/s13059-015-0723-0
Epigenome data release: a participant-centered approach to privacy protection
resolves10.1136/bmjopen-2015-010243
Other side of the coin for personalised medicine and healthcare: content analysis of ‘personalised’ practices in the literature
resolves10.1016/j.chembiol.2017.05.024
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
resolves10.1101/gr.6665407
Prediction of individual genetic risk to disease from genome-wide association studies
The 1 reference without a DOI — listed, not checked
no DOI — not checkedThe epigenotype. 1942
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1371/journal.pgen.1007362"><img src="https://citestamp.com/citestamped/10.1371/journal.pgen.1007362/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1371/journal.pgen.1007362)